Table 1

Seroepidemiologic Effects of Influenza A(H1N1)pdm09 in Australia, New Zealand, and Singapore

James M. Trauer

, Don Bandaranayake, Robert Booy, Mark I. Chen, Michelle Cretikos, Gary K. Dowse, Dominic E. Dwyer, Michael E. Greenberg, Q. Sue Huang, Gulam Khandaker, Jen Kok, Karen L. Laurie, Vernon J. Lee, Jodie McVernon, Scott Walter, Peter G. Markey, and for the Australia, New Zealand and Singapore Pandemic Serosurveillance Study Group

Author affiliations: Author affiliations: Melbourne Sleep Disorders Centre, East Melbourne, Victoria, Australia (J.M. Trauer); Environmental Science and Research, Wallaceville, New Zealand (D. Bandaranayake, Q.S. Huang); National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia (R. Booy, G. Khandaker); National University Health System, Singapore (M.I. Chen); University of Sydney, Sydney, New South Wales, Australia (M. Cretikos); Communicable Disease Control Directorate, Shenton Park, Western Australia, Australia (G.K. Dowse); Centre for Infectious Diseases and Microbiology, Westmead (D.E. Dwyer, J. Kok); CSL Limited, Parkville, Victoria, Australia (M.E. Greenberg); World Health Organization Collaborating Centre for Reference and Research in Influenza, North Melbourne, Victoria, Australia (K.L. Laurie); World Health Organization, Geneva, Switzerland (V.J. Lee); Melbourne School of Population Health, Parkville (J. McVernon); Centre for Epidemiology and Research, North Sydney, New South Wales, Australia (S. Walter; Centre for Disease Control, Tiwi, Northern Territory, Australia (P.G. Markey)

Main Article

Characteristics of collections included in database to estimate population attach rates of influenza A (H1N1) 2009 in the Southern Hemisphere, winter 2009*

Code (ref. no.)	Study design	No. assays by redefined phase	Population	Age range, y†	Study exclusions	Enrollment	Region	Spec-imen type	Testing lab-oratory	RBC species	Control serum specimen	Monovalent pandemic vaccine effect	Notes and exclusions for analysis
A (16)	Pre cross-section	524 pre	Outpatients	1–99	None	Opportunistic from stored specimens	NZ	Serum	ESR	Guinea pig	Human and ferret	Not applicable	None
B (16)	Post cross-section	1,147 post	Primary care patients	1–89	None	Active recruitment of registered GP patients	NZ	Serum	ESR	Guinea pig	Human and ferret	Collection prior to vaccination program	None
C (16)	Post cross-section	532 post	Health care workers‡	21–109	None	Active recruitment of hospital and clinic staff	NZ	Serum	ESR	Guinea pig	Human and ferret	Collection prior to vaccination program	None
D (7)	Pre cross-section	152 pre	Residents of aged-care facilities‡	59–100	None	Outbreak investigations of non-H1N1 viruses	NSW	Serum	CIDMLS	Human, O negative	Human	Not applicable	None
E (17)	Prospective cohort (pre and post collections)	788 pre	Community residents	21–74	None	Sub-cohort of existing cohort collection	Singapore	Serum	WHO-CC	Turkey	Human and ferret	Collection prior to vaccination program	None
E (17)		671 intra
F (17)		689 post
	Prospective cohort (pre and post collections)	1 pre	Healthcare workers‡	20–67	None	Email and word of mouth staff recruitment at hospital	Singapore	Serum	WHO-CC	Turkey	Human and ferret	Collection prior to vaccination program	None
		1,138 intra
		391 post
G (17)	Prospective cohort (pre and post collections)	300 intra	Staff and residents of long-term care facilities‡	19–109	None	Active recruitment by invitation	Singapore	Serum	WHO-CC	Turkey	Human and ferret	Collection prior to vaccination program	None
G (17)	Prospective cohort (pre and post collections)	250 post	Staff and residents of long-term care facilities‡	19–109	None	Active recruitment by invitation	Singapore	Serum	WHO-CC	Turkey	Human and ferret	Collection prior to vaccination program	None
H (17)	Prospective cohort (pre and post collections)	1,915 intra	Military personnel‡	18–62	None	Active recruitment by invitation	Singapore	Serum	WHO-CC	Turkey	Human and ferret	Collection prior to vaccination program	None
H (17)	Prospective cohort (pre and post collections)	637 post	Military personnel‡	18–62	None	Active recruitment by invitation	Singapore	Serum	WHO-CC	Turkey	Human and ferret	Collection prior to vaccination program	None
I (8)	Pre and post cross-sections	447 pre	Community residents	0–19	Respiratory infection indication for testing	Opportunistic from pathology laboratory	WA	Serum	WHO-CC	Turkey	Human and ferret	Collection prior to vaccination program	Gender unavailable
		221 intra
		229 post
J (8)	Pre and post cross-sections	201 pre	Pregnant women‡	21–45	Respiratory infection indication for testing	Opportunistic from pathology laboratory	WA	Serum	WHO-CC	Turkey	Human and ferret	Collection prior to vaccination program	None
		170 intra
		116 post
K (9)	Pre and post- cross-sections	474 pre	Outpatients	0–100	Influenza serologic testing	Opportunistic from pathology laboratories	NSW	Serum or lithium-heparin plasma	CIDMLS	Human, O negative	Human	Collection prior to vaccination program	Gender unavailable for 164 pre-pandemic assays
		750 intra
		497 post
L (10)	RCT of pandemic vaccine (pre-vaccine collection)	166 intra	Healthy adults	.	Pregnancy	Active recruitment of volunteers	Adelaide	Serum	Focus	Turkey	Human	Collection prior to vaccination program	Postvaccinationassays excluded
M (11)	Postpandemic cross-section with retrospective assessment of seroconversion	125 intra	Persons infected with HIV‡	19–77	None	Opportunistic testing of specimens submitted for HIV load monitoring	NSW	Plasma	CIDMLS	Human O-negative	Human	Collection prior to vaccination program	Retrospective assays excluded
M (11)		74 post	Persons infected with HIV‡	19–77	None		NSW	Plasma	CIDMLS	Human O-negative	Human	Collection prior to vaccination program	Retrospective assays excluded
N (12)	Pre and post cross-sections	404 pre	Blood donors	16–78	None	Opportunistic collection from donated blood units	Cairns, Townsville, Brisbane, Hobart, Melbourne, Newcastle, Perth, Sydney	Plasma	WHO-CC	Turkey	Human and ferret	Vaccination status checked if titer raised	None
		92 intra
		779 post
O (13)	RCT of pandemic vaccine (pre-vaccine collection)	290 intra	Community volunteers	0–8	Gestational age <36 wk, investigational vaccine	Active recruitment through tertiary hospitals	Adelaide, Brisbane, Melbourne, Perth, Sydney	Serum	Focus	Turkey	Human	Collection prior to vaccination program	Postvaccination assays excluded
O (13)	RCT of pandemic vaccine (pre-vaccine collection)	73 post	Community volunteers	0–8	Gestational age <36 wk, investigational vaccine	Active recruitment through tertiary hospitals	Adelaide, Brisbane, Melbourne, Perth, Sydney	Serum	Focus	Turkey	Human	Collection prior to vaccination program	Postvaccination assays excluded
P (14)	Pre and post cross-sections	443 pre	Outpatients	0–97	None	Opportunistic from pathology laboratory	NT	Serum	WHO-CC	Turkey	Human and ferret	Collection prior to vaccination program	None
		2 intra
		1,689 post
Q (unpub.)	Post cross-sections	65 post	Hemo-dialysis patients‡	43–88	None	Prevaccination blood sample	NSW	Serum	CIDMLS	Human, O negative	Human	Collection prior to individual vaccination	None
R (unpub.)	RCT of interferon (pre- and postintervention collections)	64 pre	Community volunteers	20–74	Chronic respiratory conditions	Active recruitment (email and newspaper)	Perth	Serum	WHO-CC	Turkey	Human and ferret	Patients receiving vaccine excluded	Postintervention assays in active treatment arm excluded
		102 intra
		87 post
S (unpub.)	Pre and post cross-sections	944 pre	Community residents	0–18	None	National pediatric serosurveillance studies	Singapore	Serum	WHO-CC	Turkey	Human and ferret	Low vaccine uptake (≈1%–2%) in population at time of collection (19)	Postvaccine assays excluded
		32 intra
		460 post

*RBC, red blood cells; pre, prepandemic phase; intra, intrapandemic phase; post, postpandemic phase; ESR, World Health Organization National Influenza Centre, Environmental Science and Research, New Zealand; CIDMLS, Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia; WHO-CC, World Health Organization Collaborating Centre for Reference and Research on Influenza, North Melbourne, Australia; Focus = Focus Diagnostics, California, USA; RCT, randomized controlled trial; GP, general practitioner; NZ, New Zealand, NSW, New South Wales; WA, Western Australia; NT, Northern Territory.
†Age range for specimens included in pre or postpandemic phases.
‡Defined as risk groups for analysis.

Main Article

References

Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Emergence of a novel swine-origin influenza A (H1N1) in virus in humans. N Engl J Med. 2009;360:2605–15. DOIPubMedGoogle Scholar
Bishop JF, Murnane MP, Owen R. Australia’s winter with the 2009 pandemic influenza A (H1N1) virus. N Engl J Med. 2009;361:2591–4. DOIPubMedGoogle Scholar
Centers for Disease Control and Prevention. Surveillance for the 2009 pandemic influenza A (H1N1) virus and seasonal influenza viruses—New Zealand, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:918–21.PubMedGoogle Scholar
Cutter JL, Ang LW, Lai FY, Subramony H, Ma S, James L. Outbreak of pandemic influenza A (H1N1-2009) in Singapore, May to September 2009. Ann Acad Med Singapore. 2010;39:273–82.PubMedGoogle Scholar
Barr IG, Cui L, Komadina N, Lee RT, Lin RT, Deng Y, A new pandemic influenza A (H1N1) genetic variant predominated in the winter 2010 influenza season in Australia, New Zealand and Singapore. Euro Surveill. 2010;15:pii19692 .PubMedGoogle Scholar
World Health Organization. Seroepidemiological studies of pandemic influenza A (H1N1) 2009 virus. Wkly Epidemiol Rec. 2010;85:229–35 .PubMedGoogle Scholar
Booy R, Khandaker G, Heron LG, Yin J, Doyle B, Tudo KK, Cross-reacting antibodies against the pandemic (H1N1) 2009 influenza virus in older Australians. Med J Aust. 2011;194:19–23.PubMedGoogle Scholar
Dowse GK, Smith DW, Kelly H, Barr I, Laurie KL, Jones AR, Incidence of pandemic (H1N1) 2009 influenza infection in children and pregnant women during the 2009 influenza season in Western Australia—a seroprevalence study. Med J Aust. 2011;194:68–72 .PubMedGoogle Scholar
Gilbert GL, Cretikos MA, Hueston L, Doukas G, O'Toole B, Dwyer DE, Influenza A(H1N1) 2009 antibodies in residents of New South Wales, Australia, after the first pandemic wave in the 2009 southern hemisphere winter. PLoS ONE. 2010;5:e12562. DOIPubMedGoogle Scholar
Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009;361:2405–13. DOIPubMedGoogle Scholar
Kok J, Tudo K, Blyth CC, Foo H, Hueston L, Dwyer DE. Pandemic H1N1 (2009) influenza virus seroconversion rates in HIV-infected individuals. J Acquir Immune Defic Syndr. 2011;56:91–4. DOIPubMedGoogle Scholar
McVernon J, Laurie K, Nolan T, Owen R, Irving D, Capper H, Seroprevalence of 2009 pandemic influenza A (H1N1) virus in Australian blood donors. Euro Surveill. 2010;15:19678.PubMedGoogle Scholar
Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, Lambert S, Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children. JAMA. 2010;303:37–46. DOIPubMedGoogle Scholar
Trauer JM, Laurie K, McDonnell J, Kelso A, Markey PG. Differential impact of pandemic (H1N1) 2009 on remote and indigenous groups in the Northern Territory, Australia. Emerg Infect Dis. 2011;17:1615–23. DOIPubMedGoogle Scholar
Grills N, Piers LS, Barr I, Vaughan LM, Lester R, Magliano DJ, A lower than expected adult Victorian community attack rate for pandemic (H1N1) 2009. Aust N Z J Public Health. 2010;34:228–31. DOIPubMedGoogle Scholar
Bandaranayake D, Huang QS, Bissielo A, Wood T, Mackereth G, Baker MG, 2009 H1N1 Serosurvey Investigation Team. Risk factors and immunity in a nationally representative population following the 2009 influenza A (H1N1) pandemic. PLoS ONE. 2010;5:e13211. DOIPubMedGoogle Scholar
Chen MI, Lee VJ, Lim WY, Barr IG, Lin RT, Koh GC, 2009 influenza A (H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore. JAMA. 2010;303:1383–91. DOIPubMedGoogle Scholar
Australian Bureau of Statistics. 3201.0 Population by age and sex, Australian states and territories, June 2010 [cited 2011 Apr 3]. http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3201.0Jun%202010?OpenDocument.
Singapore Ministry of Health. Epidemiological News Bulletin April–June 2010 [cited 2011 Jun 13]. http://www.moh.gov.sg/content/dam/moh_web/Statistics/Epidemiological_News_Bulletin/2010/ENB02Q_10.pdf
Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945–52. DOIPubMedGoogle Scholar
McCullers JA, Van De Velde LA, Allison KJ, Branumn KC, Webby RJ, Flynn PM. Recipients of vaccine against the 1976 “swine flu” have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis. 2010;50:1487–92. DOIPubMedGoogle Scholar
Miller E, Hoschler K, Hardelid P, Standford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010;375:1100–8. DOIPubMedGoogle Scholar
Wu JT, Ma ES, Lee CK, Chu DK, Ho PL, Shen AL, The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis. 2010;51:1184–91. DOIPubMedGoogle Scholar
Tandale BV, Pawar SD, Gurav YK, Chadha MS, Koratkar SS, Shelke VN, Seroepidemiology of pandemic influenza A (H1N1) 2009 virus infections in Pune, India. BMC Infect Dis. 2010;10:255. DOIPubMedGoogle Scholar
Lowen AC, Steel J, Mubareka S, Palese P. High temperature (30°C) blocks aerosol but not contact transmission of influenza virus. J Virol. 2008;82:5650–2. DOIPubMedGoogle Scholar
Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin Virol. 2011;50:194–200. DOIPubMedGoogle Scholar
Falagas ME, Koletsi PK, Baskouta E, Rafailidis PI, Dimopoulos G, Karageorgopoulos DE, H1N1 2009 influenza: review of the Southern Hemisphere experience. Epidemiol Infect. 2011;139:27–40. DOIPubMedGoogle Scholar
Riera M, Payeras A, Marcos MA, Viasus D, Farinas MC, Segura F, Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicentre study. AIDS. 2010;24:2461–7. DOIPubMedGoogle Scholar
Gordon CL, Johnson PD, Permezel M, Holmes NE, Gutteridge G, McDonald CF, Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency. Clin Infect Dis. 2010;50:672–8.PubMedGoogle Scholar
Kelly H, Mercer G, Cheng A. Quantifying the risk of pandemic influenza in pregnancy and indigenous people in Australia in 2009. Euro Surveill. 2009;14:pii19441.PubMedGoogle Scholar
Aho M, Lyytikaïnen O, Nyholm JE, Kuitunen T, Rönkkö E, Santanen R, Outbreak of 2009 pandemic influenza A(H1N1) in a Finnish garrison— a serological survey. Euro Surveill. 2010;15:19709.PubMedGoogle Scholar
Kelly H, Riddell MA, Gidding HF, Nolan T, Gilbert GL. A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine. 2002;20:3130–6. DOIPubMedGoogle Scholar
Australian Government Department of Health and Ageing. Review of Australia’s health sector response to pandemic (H1N1) 2009: lessons identified [cited 2012 Jul 5]. http://www.flupandemic.gov.au/ internet/panflu/publishing.nsf/Content/review-2011/$File/lessons%20identified-oct11.pdf.
Paine S, Mercer GN, Kelly PM, Bandaranayake D, Baker MG, Huang QS, Transmissibility of 2009 pandemic influenza A(H1N1) in New Zealand: effective reproductive number and influence of age, ethnicity and importations. Euro Surveill. 2010;15:19591.PubMedGoogle Scholar
Tay J, Ng YF, Cutter JL, James L, Influenza A. H1N1–2009) pandemic in Singapore – public health control measures implemented and lessons learnt. Ann Acad Med Singapore. 2010;39:313–24.PubMedGoogle Scholar
Kok J, Dwyer DE. How common was 2009 pandemic influenza A H1N1 infection? Lancet Infect Dis. 2011;11:423–4. DOIPubMedGoogle Scholar
Chen MI, Barr IG, Koh GC, Lee VJ, Lee CP, Shaw R, Serological response in RT-PCR confirmed H1N1–2009 influenza a by hemagglutination inhibition and virus neutralisation assays: an observational study. PLoS ONE. 2010;5:e12474. DOIPubMedGoogle Scholar

Main Article

¹A list of the group’s members can be found at the end of this article.

Page created: December 20, 2012

Page updated: December 20, 2012

Page reviewed: December 20, 2012

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.